| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| ADORA1 | ADORA3 | ENSP00000356205 | ENSP00000358730 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | 0.920 |
| ADORA1 | ADRA2B | ENSP00000356205 | ENSP00000480573 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | Alpha-2B adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol; Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. [...] | 0.921 |
| ADORA1 | CHRM2 | ENSP00000356205 | ENSP00000399745 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | Muscarinic acetylcholine receptor M2; The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol; Cholinergic receptors muscarinic | 0.903 |
| ADORA1 | CHRM4 | ENSP00000356205 | ENSP00000409378 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | Muscarinic acetylcholine receptor M4; The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase; Cholinergic receptors muscarinic | 0.911 |
| ADORA1 | KNG1 | ENSP00000356205 | ENSP00000265023 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | Kininogen-1; (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects- (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation [...] | 0.945 |
| ADORA1 | OPRL1 | ENSP00000356205 | ENSP00000336764 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | Nociceptin receptor; G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception [...] | 0.925 |
| ADORA1 | P2RY12 | ENSP00000356205 | ENSP00000307259 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | P2Y purinoceptor 12; Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation; P2Y receptors | 0.958 |
| ADORA1 | P2RY13 | ENSP00000356205 | ENSP00000320376 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | P2Y purinoceptor 13; Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system; P2Y receptors | 0.950 |
| ADORA1 | P2RY14 | ENSP00000356205 | ENSP00000308361 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | P2Y purinoceptor 14; Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP; P2Y receptors | 0.946 |
| ADORA1 | P2RY4 | ENSP00000356205 | ENSP00000363643 | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | P2Y purinoceptor 4; Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP | 0.956 |
| ADORA3 | ADORA1 | ENSP00000358730 | ENSP00000356205 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Adenosine receptor A1; Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase; Belongs to the G-protein coupled receptor 1 family | 0.920 |
| ADORA3 | ADRA2B | ENSP00000358730 | ENSP00000480573 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Alpha-2B adrenergic receptor; Alpha-2 adrenergic receptors mediate the catecholamine- induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine > norepinephrine > epinephrine = oxymetazoline > dopamine > p-tyramine = phenylephrine > serotonin > p-synephrine / p-octopamine. For antagonists, the rank order is yohimbine > chlorpromazine > phentolamine > mianserine > spiperone > prazosin > alprenolol > propanolol > pindolol; Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. [...] | 0.923 |
| ADORA3 | CHRM2 | ENSP00000358730 | ENSP00000399745 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Muscarinic acetylcholine receptor M2; The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then triggers calcium ion release into the cytosol; Cholinergic receptors muscarinic | 0.900 |
| ADORA3 | CHRM4 | ENSP00000358730 | ENSP00000409378 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Muscarinic acetylcholine receptor M4; The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase; Cholinergic receptors muscarinic | 0.906 |
| ADORA3 | KNG1 | ENSP00000358730 | ENSP00000265023 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Kininogen-1; (1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects- (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation [...] | 0.940 |
| ADORA3 | OPRL1 | ENSP00000358730 | ENSP00000336764 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | Nociceptin receptor; G-protein coupled opioid receptor that functions as receptor for the endogenous neuropeptide nociceptin. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling via G proteins mediates inhibition of adenylate cyclase activity and calcium channel activity. Arrestins modulate signaling via G proteins and mediate the activation of alternative signaling pathways that lead to the activation of MAP kinases. Plays a role in modulating nociception [...] | 0.953 |
| ADORA3 | P2RY12 | ENSP00000358730 | ENSP00000307259 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 12; Receptor for ADP and ATP coupled to G-proteins that inhibit the adenylyl cyclase second messenger system. Not activated by UDP and UTP. Required for normal platelet aggregation and blood coagulation; P2Y receptors | 0.968 |
| ADORA3 | P2RY13 | ENSP00000358730 | ENSP00000320376 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 13; Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system; P2Y receptors | 0.966 |
| ADORA3 | P2RY14 | ENSP00000358730 | ENSP00000308361 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 14; Receptor for UDP-glucose and other UDP-sugar coupled to G-proteins. Not activated by ATP, ADP, UTP or ATP; P2Y receptors | 0.955 |
| ADORA3 | P2RY4 | ENSP00000358730 | ENSP00000363643 | Transmembrane domain-containing protein TMIGD3; Isoform 1- Plays a suppressive role in osteosarcoma malignancy by inhibiting NF-kappa-B activity; Adenosine receptors | P2Y purinoceptor 4; Receptor for UTP and UDP coupled to G-proteins that activate a phosphatidylinositol-calcium second messenger system. Not activated by ATP or ADP | 0.956 |
